PA8608601A1 - Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - Google Patents

Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Info

Publication number
PA8608601A1
PA8608601A1 PA20048608601A PA8608601A PA8608601A1 PA 8608601 A1 PA8608601 A1 PA 8608601A1 PA 20048608601 A PA20048608601 A PA 20048608601A PA 8608601 A PA8608601 A PA 8608601A PA 8608601 A1 PA8608601 A1 PA 8608601A1
Authority
PA
Panama
Prior art keywords
compounds
treatment
neurodegenerative disorders
formula
oxazol
Prior art date
Application number
PA20048608601A
Other languages
English (en)
Inventor
Yuhpyng Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8608601A1 publication Critical patent/PA8608601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA EN DONDE R3, R5, R6, R7 Y Z, ASI COMO OTROS VALORES ENUMERADOS CON RELACION A R3, R5, R6, R7 Y Z SON COMO SE LOS DEFINE. LOS COMPUESTOS DE FORMULA I PRESENTAN ACTIVIDAD INHIBIDORA DE LA PRODUCCION DE PEPTIDO Aß. ESTA INVENCION SE REFIERE ADEMAS A COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR ENFERMEDADES, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS, I.E. ENFERMEDAD DE ALZHEIMER, EN UN MAMIFERO, QUE COMPRENDEN COMPUESTOS DE FORMULA I.
PA20048608601A 2003-08-06 2004-08-06 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos PA8608601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49288403P 2003-08-06 2003-08-06
US49802803P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
PA8608601A1 true PA8608601A1 (es) 2005-03-03

Family

ID=34197958

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048608601A PA8608601A1 (es) 2003-08-06 2004-08-06 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Country Status (13)

Country Link
US (1) US7112599B2 (es)
EP (1) EP1653952A4 (es)
JP (1) JP2007501244A (es)
AR (1) AR046327A1 (es)
BR (1) BRPI0413349A (es)
CA (1) CA2534529A1 (es)
MX (1) MXPA06001480A (es)
PA (1) PA8608601A1 (es)
PE (1) PE20050337A1 (es)
SV (1) SV2005001840A (es)
TW (1) TW200510351A (es)
UY (1) UY28458A1 (es)
WO (1) WO2005016267A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1730119T3 (pl) * 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
WO2007034326A2 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
UA117913C2 (uk) * 2012-05-31 2018-10-25 Фінекс Фармас'Ютікалс Аг КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
KR20210005593A (ko) * 2018-03-23 2021-01-14 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
CN113651805B (zh) * 2021-07-19 2023-07-25 安徽医科大学 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094462A (en) * 1961-09-18 1963-06-18 Mcneilab Inc Therapeutic reaction complex for muscle relaxation
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1264258A (es) * 1970-10-10 1972-02-16
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
KR20000005291A (ko) * 1996-06-25 2000-01-25 다케다 야쿠힌 고교 가부시키가이샤 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
AU4181000A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
CA2501803A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
CA2501799C (en) * 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
PL211061B1 (pl) * 2002-12-23 2012-04-30 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, ich zastosowanie i kompozycja farmaceutyczna
CA2512602A1 (en) * 2003-01-13 2004-07-29 F. Hoffmann-La Roche Ag Benzoxazole derivatives and their use as adenosine receptor ligands

Also Published As

Publication number Publication date
SV2005001840A (es) 2005-11-04
US20050032859A1 (en) 2005-02-10
UY28458A1 (es) 2005-03-31
WO2005016267A2 (en) 2005-02-24
CA2534529A1 (en) 2005-02-24
MXPA06001480A (es) 2006-05-15
JP2007501244A (ja) 2007-01-25
AR046327A1 (es) 2005-12-07
PE20050337A1 (es) 2005-06-06
US7112599B2 (en) 2006-09-26
EP1653952A2 (en) 2006-05-10
EP1653952A4 (en) 2007-04-04
WO2005016267A3 (en) 2005-04-21
TW200510351A (en) 2005-03-16
BRPI0413349A (pt) 2006-10-10

Similar Documents

Publication Publication Date Title
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8608301A1 (es) Compuestos heteroarilo de 6 miembros de heteroarilo para el tratamiento de enfermedades neurogenerativas
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
UY28144A1 (es) Agentes terapéuticos
PA8609801A1 (es) Compuestos para el tratamiento de transtornos neurogenerativos
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
PA8601101A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
DOP2003000728A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos
GT200400227A (es) Compuestos para el tratamiento de trastornos neurodegenerativos.
UY29286A1 (es) Agentes terapeuticos 1